Current treatments for schizophrenia, which primarily work through D2 dopamine receptor antagonism, are most effective for the positive symptoms, but show little efficacy for the negative symptoms or cognitive deficits of the disease (Mailman and Murthy, 2010). Here, DRD2 is linked to Cognitive impairment.